Now since 2015 I’ve had my own consultancy in this space. Then I was part of Oracle Health Sciences for three years until leaving Oracle to go to another life sciences SaaS company called Viva Systems, which some of our listeners may be familiar with Viva and I was brought there to build up the North American Professional services team as Viva moved into serving the pharmaceutical development side of their biopharmaceutical customer base. I was at Phase Forward for a little more than 10 years through our IPO and through I think eight or nine acquisitions in operational and cultural integrations, some of which we did better than others. I wasn’t a founder, but I was pretty early and got to experience the phenomenon of compressed experience that you get in the startup world. We were doing what now would be called cloud-based software systems for the testing of pharmaceutical products and medical device products and drug and medical device safety. Paul Bleiser and Paul was the founding CEO and visionary of a pioneering company called Phase Forward. I started asking around and looking for opportunities and I ended up meeting Dr. So I thought, oh, this sounds like it could be interesting. Right around the turn of the millennium, all of my buddies were joining software startups. I started my career in mechanical and aerospace engineering and actually had pretty traditional engineering roles for the first eight years or so. It’s good to talk to you again, and I appreciate you being here.ĭavid, I wanted to maybe start going back a little bit into your background and maybe just ask the question so how did you find yourself here in this industry, in the biopharma industry? David, thanks for joining me today.Ĭharles, thanks very much. ![]() David’s career has included past leadership experience with many of the leading technology companies that served the biopharma industry, including Viva Systems, Oracle Health Services, and Phase Forward. To explore this topic and more, I’m joined by David Fishbach, founder and principal of Xcel Executive Business Advisors, which provides corporate strategy, operations and leadership development for technology, life sciences and healthcare. In our view, technology holds the potential to adjust address some long-standing issues and research, including a lack of accessibility and diversity that may pave way to a convergence of clinical care and research. The FDA has looked favorably on technology enabled and decentralized clinical trial models even prior to COVID, but the pandemic has led to broader adoption of these technologies and models clearing the way for technology companies to continue disrupting the industry at greater scale. Today we’ll be talking about clinical research and the landscape for clinical research is evolving with many sponsors looking to leverage technology to address inefficiencies in the traditional site-based clinical trial process and counter the rising cost of developing new therapies. Today’s podcast is part of our monthly series that continues Cowan’s efforts to bring together thought leaders, innovators, and investors to discuss how the convergence of healthcare technology and consumerism is changing the way we look at health, healthcare, and the healthcare system. Hello, my name is Charles Rhyee, Cowan’s Healthcare Technology Analyst and welcome to the Cowan Future Health podcast. Join us as we converse with the top minds who are influencing our global sectors. ![]() Welcome to Cowan Insights, a space that brings leading thinkers together to share insights and ideas shaping the world around us. ![]() They also discuss the FDA’s favorable views on technology-enabled and decentralized clinical trial models, and its potential disrupt the industry by addresses some longstanding issues in research, including a lack of accessibility & diversity. They discuss the evolution of the clinical research landscape, how technology addresses inefficiencies in the traditional site-based clinical trial based process, and how it counters the rising cost of developing new therapies. David’s career has included past leadership experience with many technology companies that serve the biopharma industry including Veeva Systems, Oracle Health Services and PhaseForward. In this episode of TD Cowen’s FutureHealth Podcast Series, David Fishbach, Founder & Principal of Excel Executive Business Advisors, which provides corporate strategy, operations, and leadership development for technology, life sciences, and healthcare joins Charles Rhyee, Cowen’s Health Care Technology Analyst in this episode. Listen on Apple Podcasts Listen on Spotify Listen on SoundCloud
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |